Trading Halted on Euronext Paris Ahead of Global Offering Pricing

summarizeSummary

Nanobiotix halted trading on Euronext Paris to prepare for the pricing announcement of its $87 million global offering, a key step in its capital raise.

check_boxKey Events

• Trading Halt for Offering Pricing

  Trading of ordinary shares on Euronext Paris has been temporarily halted at the company's request to confirm investor allocations and announce the pricing of its global offering.

• Imminent Offering Pricing

  The halt precedes the announcement of the final terms for the previously launched global offering, which aims to raise approximately $87 million.

• Significant Capital Raise

  The offering represents a substantial capital raise for Nanobiotix, providing funds for its operations and clinical development.

auto_awesomeAnalysis

Nanobiotix has temporarily halted trading of its ordinary shares on Euronext Paris to finalize investor allocations and announce the pricing of its previously launched global offering. This offering, which aims to raise approximately $87 million, is a significant capital raise for the company. The halt indicates that the final terms of this dilutive financing are imminent, which will provide clarity on the company's near-term financial runway.